Rafiee, Roya
Chauhan, Lata
Alonzo, Todd A.
Wang, Yi-Cheng
Elmasry, Ahlam
Loken, Michael R.
Pollard, Jessica
Aplenc, Richard
Raimondi, Susana
Hirsch, Betsy A.
Bernstein, Irwin D.
Gamis, Alan S.
Meshinchi, Soheil
Lamba, Jatinder K. http://orcid.org/0000-0003-0411-0007
Funding for this research was provided by:
St. Baldrick's Foundation
Article History
Received: 27 February 2019
Accepted: 15 April 2019
First Online: 21 May 2019
Conflict of interest
: M.R.L. is employee of Hemtologics Inc., I.D.B. has royalty from CD33 antibody used for leukemia diagnosis from Becton Dickinson; royalty for intellectual property on Notch-induced cord blood stem cell expansion. A.S.G. has consulting or advisory role with Pfizer, Novartis. R.A. has honoraria from Sigma-Tau Pharmaceuticals. The remaining authors declare that they have no conflict of interest.